remibrutinib small molecule drug acts brutons tyrosine kinase btk inhibitor development treatment chronic spontaneous november novartis announced compound demonstrated clinically meaningful statistically significant reduction urticaria activity vs placebo phase iii httpsenwikipediaorgwikiremibrutinib